This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects

This study has been completed.
Information provided by:
Lantheus Medical Imaging Identifier:
First received: September 9, 2005
Last updated: June 1, 2011
Last verified: June 2011
The purpose of this Phase I-II multicenter clinical trial is to establish dosimetry and safety profiles for CARDIOLITE® (Technetium Tc99m Sestamibi) in pediatric subjects.

Condition Intervention Phase
Kawasaki Disease Drug: Technetium Tc99m Sestamibi Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Phase I-II, Open-Label, Multicenter Trial to Determine the Dosimetry and Safety of Technetium Tc99m Sestamibi in Pediatric Subjects

Resource links provided by NLM:

Further study details as provided by Lantheus Medical Imaging:

Primary Outcome Measures:
  • Determination of the absorbed radiation dose of Sestamibi in subjects will be evaluated at the end of the study through measurements of PK (blood and urine) up to 8 hours, dosimetry for 8 hours and image biodistribution for up to 8 hours [ Time Frame: Following administration of Technetium Tc99m Sestamibi ]

Secondary Outcome Measures:
  • A determination of the safety of Sestamibi will be evaluated at the end of the study through adverse and serious adverse events reported and evaluating vital signs, ECGs, physical exams and laboratory tests for each subject [ Time Frame: Following administration of Technetium Tc99m Sestamibi ]

Enrollment: 79
Study Start Date: January 2005
Study Completion Date: June 2007
Primary Completion Date: May 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Technetium Tc99m Sestamibi
    Rest and/or stress SPECT imaging study

Ages Eligible for Study:   4 Years to 16 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have been scheduled to undergo a clinically indicated rest or stress CARDIOLITE® MPI scan.
  • Be able to comply with imaging requirements permitting completion of rest or stress CARDIOLITE® whole-body scans and SPECT imaging procedures without the use of sedation.

Exclusion Criteria:

  • Have a terminal illness where expected survival is ≤6 months
  • Have known clinically significant laboratory abnormalities (creatine, liver enzymes, platelet count).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00162045

United States, Florida
Jackson Memorial Hospital
Miami, Florida, United States, 33136
United States, Hawaii
Local Institution
Honolulu, Hawaii, United States, 96810
United States, Illinois
University of Chicago Children's Hospital
Chicago, Illinois, United States, 60637
United States, Pennsylvania
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
United States, Washington
Children's Hospital and Regional Medical Center
Seattle, Washington, United States, 98105
United States, Wisconsin
Children's Hospital of Wisconsin
Wauwatosa, Wisconsin, United States, 29425
Canada, British Columbia
Local Institution
Vancouver, British Columbia, Canada, V6H 3V4
Local Institution
Changhua, Taiwan
Local Institution
Taichung, Taiwan
Sponsors and Collaborators
Lantheus Medical Imaging
Study Director: Qi Zhu, MD Lantheus Medical Imaging
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Qi Zhu, MD Senior Medical Director, Lantheus Medical Imaging Identifier: NCT00162045     History of Changes
Other Study ID Numbers: DuP 843-201
Study First Received: September 9, 2005
Last Updated: June 1, 2011

Additional relevant MeSH terms:
Mucocutaneous Lymph Node Syndrome
Vascular Diseases
Cardiovascular Diseases
Lymphatic Diseases
Skin Diseases, Vascular
Skin Diseases
Technetium Tc 99m Sestamibi
Molecular Mechanisms of Pharmacological Action processed this record on August 18, 2017